Viral Hepatitis Market Report 2026

The viral hepatitis market size has grown steadily in recent years. It will grow from $16.77 billion in 2025 to $17.37 billion in 2026 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to improvements in blood screening practices, expansion of vaccination coverage, availability of antiviral medications, increased disease awareness, establishment of public health hepatitis programs.

The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $20.85 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to increasing focus on hepatitis elimination initiatives, rising investments in novel antiviral drugs, expansion of point-of-care diagnostics, growing adoption of combination therapies, increasing global screening programs. Major trends in the forecast period include increasing adoption of advanced antiviral therapies, rising use of molecular diagnostic techniques, growing focus on early disease detection, expansion of vaccination programs, enhanced monitoring of chronic hepatitis cases.

The rising prevalence of hepatitis is expected to drive the growth of the viral hepatitis market in the coming years. Hepatitis is a liver infection caused by various infectious viruses and non-infectious substances, which can lead to multiple health complications. Viruses such as hepatitis A, B, C, D, and E can cause viral hepatitis, resulting in liver inflammation and damage. For instance, in April 2025, according to the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union (EU) health agency, 30 EU/EEA Member States reported 37,766 newly diagnosed cases of hepatitis B virus (HBV) infection in 2023, corresponding to a crude rate of 8.1 cases per 100,000 population. Therefore, the rising prevalence of hepatitis is propelling the growth of the viral hepatitis market.

Major companies operating in the viral hepatitis market are focusing on incorporating advanced immunoassay technologies, such as automated dual-marker immunoassays, to enhance early detection and disease monitoring. Automated dual-marker immunoassays are in-vitro diagnostic tests that simultaneously detect both antigen and antibody from a single sample, enabling near-real-time infection analysis, shortened diagnostic windows, and improved screening efficiency. For instance, in July 2023, Roche Diagnostics India, an India-based provider of in-vitro diagnostics and laboratory automation solutions, launched Elecsys HCV Duo, a dual-antigen and antibody immunoassay designed to detect hepatitis C virus. It features simultaneous independent detection of HCV core antigen and anti-HCV antibodies from a single serum or plasma sample, allowing significantly earlier diagnosis of active HCV infection and compatibility with automated analyzer platforms such as cobas e 402 and e 801. Elecsys HCV Duo enhances early detection, enables faster linkage to care, streamlines diagnostic workflows, and reduces the burden on healthcare systems.

In November 2023, GSK plc, a U.K.-based pharmaceutical company, acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. With rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug, GSK aims to expand its portfolio and strengthen its position in chronic hepatitis B treatment by adding a promising new therapy. Janssen Pharmaceuticals, a Belgium-based subsidiary of Johnson & Johnson, specializes in developing treatments for infectious diseases, including chronic hepatitis B.

Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

North America was the largest region in the viral hepatitis market in 2025. The regions covered in the viral hepatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral hepatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the viral hepatitis market by increasing costs of imported diagnostic kits, antiviral drug ingredients, laboratory equipment, and vaccine components. Healthcare providers and pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported raw materials, while Asia-Pacific faces cost pressures on vaccine and generic drug production. These tariffs are increasing treatment costs and affecting supply chain efficiency. However, they are also promoting domestic pharmaceutical manufacturing, regional sourcing of active ingredients, and long-term resilience in hepatitis treatment supply chains.

The viral hepatitis market research report is one of a series of new reports that provides viral hepatitis market statistics, including viral hepatitis industry global market size, regional shares, competitors with a viral hepatitis market share, detailed viral hepatitis market segments, market trends and opportunities, and any further data you may need to thrive in the viral hepatitis industry. This viral hepatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral hepatitis is a group of infectious diseases caused by different viruses (hepatitis A, B, C, D, and E) that primarily affect the liver. Symptoms vary depending on the specific virus but commonly include fatigue, jaundice, abdominal pain, nausea, vomiting, and fever.

The main types of viral hepatitis include hepatitis A, hepatitis B, hepatitis C, and others. Hepatitis A is a liver disease caused by the hepatitis A virus that can potentially be serious. Diagnosis methods include liver biopsy, blood tests, imaging tests, and others, while treatments include antiviral drugs, surgery, vaccines, immune-modulating drugs, and more. Routes of administration include oral, parenteral, and others. These treatments are used in hospitals, specialty clinics, homecare, and other healthcare settings.

The viral hepatitis market consists of revenues earned by entities by providing services such as treatment, testing, awareness programs and diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral hepatitis market also includes the sales of treatments such as vaccines and medication. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.